Research Center Principe Felipe
The Principe Felipe Research Center (CIPF) is a research center in Spain dedicated to biomedical studies inaugurated on March 17, 2005 by Their Royal Highnesses the Prince and Princess of Asturias with the aim of tackling new advances in biomedical research and promoting scientific work of excellence. The CIPF gathers the research tradition of the previous Cytological Research Institute and the Valencian Foundation for Biomedical Research, with the aim of strengthening and expanding it. Over the years, the CIPF has established itself as a reference center both nationally and internationally.
The CIPF is a private foundation attached to the Ministry of Health of the Generalitat Valenciana.
For almost 50 years, the researchers at the Príncipe Felipe Research Center have made a great effort to position the research carried out at the center within the international framework of excellence. Great advances have been made in such important topics as regenerative medicine, cancer, new therapies, neuronal deterioration, etc.
Its objective is biomedical research including basic research on genes, targets, molecular and cellular processes, nanomedicine and computational medicine as well as its translation to clinical practice with special interest in personalized medicine, cancer], rare, metabolic diseases, and cognitive impairment and functional.
The CIPF is a private foundation attached to the Ministry of Health of the Generalitat Valenciana.
For almost 50 years, the researchers at the Príncipe Felipe Research Center have made a great effort to position the research carried out at the center within the international framework of excellence. Great advances have been made in such important topics as regenerative medicine, cancer, new therapies, neuronal deterioration, etc.
Its objective is biomedical research including basic research on genes, targets, molecular and cellular processes, nanomedicine and computational medicine as well as its translation to clinical practice with special interest in personalized medicine, cancer], rare, metabolic diseases, and cognitive impairment and functional.
